Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
8 things to know about aflibercept 8 mg for retinal vascular disease | Ophthalmology Times
The US Food and Drug Administration (FDA) approved aflibercept 8 mg (EYLEA HD) for the treatment of patients with macular edema following retinal vein occlusion (RVO) with up to 8-week dosing after an initial dosing period last month. The latest…
From bench to bedside: Evolving realities of gene therapy for inherited retinal diseases | Ophthalmology Times
(Image Credit: AdobeStock/artacet) In recent years, gene therapy has emerged from the shadows of theoretical potential into the spotlight of clinical reality. The approval of voretigene neparvovec-rzyl (Luxturna; Spark Therapeutics) marked a historic moment as the first gene therapy for…
The Atrophy Advisor: An online tool to inform GA treatment decisions | Ophthalmology Times
(Image Credit: AdobeStock/NINENII) An online tool, Atrophy Advisor, was developed to guide physicians regarding treatments for patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD). The tool, available at atrophyadvisor.com, integrates GA progression and personalized lifespan estimates to…
NCX 470 advances toward US, China NDA submissions for NCX 470 | Ophthalmology Times
(Image Credit: AdobeStock) Nicox has announced it has acquired and analyzed all key data required to support the submission of New Drug Applications (NDAs) in the US and China for NCX 470.1 NCX 470 is Nicox’s lead clinical product candidate…
Unmet Needs in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Management and Monitoring Strategies in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
FDA extends Aldeyra’s reproxalap PDUFA after requesting additional clinical study report | Ophthalmology Times
(Image Credit: AdobeStock) The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for Aldeyra’s New Drug Application (NDA) for reproxalap for the treatment of dry eye disease (DED). The new…
Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal | Ophthalmology Times
This segment examines how the advent of higher-dose and dual-pathway anti-VEGF agents has reshaped treatment strategies for retinal vascular diseases. The discussion underscores how aflibercept 8 mg and faricimab have improved anatomic outcomes and extended dosing intervals, offering meaningful—though patient-specific—reductions…
Argenx discontinues phase 3 UplighTED trials of efgartigimod SC in thyroid eye disease | Ophthalmology Times
(Image Credit: AdobeStock/SnapVault) Argenx SE has discontinued the phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED). According to the company, the trial is being discontinued based…
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy | Ophthalmology Times
(Image Credit: AdobeStock/9dreamstudio) Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is a polysialic acid-coated nanoparticle in which the polysialic acid…